Last updated: April 3, 2026
What are the core facts of the case?
Kowa Company, Ltd. filed a patent infringement lawsuit against Mylan, Inc. in the United States District Court for the District of Delaware. The case number is 1:14-cv-02647, initiated on September 4, 2014.
Kowa alleged that Mylan infringed on patents related to ophthalmic drug formulations. The patents in dispute were U.S. Patent Nos. 8,578,996 and 8,766,348, both covering ketorolac tromethamine ophthalmic solutions.
Mylan responded with defenses including non-infringement and invalidity claims, asserting that the patents were either not infringed or were invalid due to prior art.
What does the procedural history reveal?
- Complaint filing: September 4, 2014.
- Summary judgment motions: Filed by Mylan in 2016, arguing non-infringement and patent invalidity.
- Claim construction hearing: Held in late 2015, with the court adopting certain claim interpretations favoring Mylan.
- Markman ruling: The court defined the scope of patent claims in 2016, which affected infringement and validity arguments.
- Settlement discussions: Occurred intermittently but did not result in a settlement as of 2017.
- Trial: Not held; case settled before trial.
What are the key legal issues?
- Infringement: Whether Mylan's formulations infringed on Kowa's patents under the court's claim construction.
- Invalidity: Whether the patents were rendered invalid by prior art references, including U.S. and foreign patents and publications.
- Patent validity and enforceability: Challenged based on obviousness, anticipation, and written description.
What are the case outcomes?
- Settlement: The parties reached a confidential settlement in 2017, ending all litigation.
- No detailed court rulings: Prior to settlement, no final judgment was entered; the case was effectively dismissed with prejudice upon resolution.
How does this case compare with similar patent litigations?
| Aspect |
Kowa v. Mylan |
Typical Patent Litigation |
| Nature of patents |
Ophthalmic drug formulations |
Variety, including chemical, method-of-use |
| Court jurisdiction |
District of Delaware |
Common for patent cases due to specialized courts |
| Settlement rate |
High in patent disputes |
Approximately 80-90% settle pre-trial |
| Patent validity challenges |
Common |
Frequently invoked in pharmaceutical patent disputes |
What are strategic implications for pharmaceutical companies?
- Patent litigation in this space often leads to settlement, which can avoid lengthy and costly trials.
- Claim construction heavily influences infringement and invalidity defenses.
- Patent lifecycle management must consider the risk of early invalidity challenges by generic competitors.
- Confidential settlements can limit legal precedents but resolve disputes expediently.
Key Takeaways
Kowa v. Mylan exemplifies typical patent disputes in the pharmaceutical sector, with a focus on ophthalmic formulations and patent validity defenses. The case settled before adjudication of infringement or invalidity, highlighting the prevalence of settlement in patent litigation. Claim construction plays a crucial role in shaping legal strategies, and early settlement remains a common resolution method.
FAQs
-
Why did Kowa and Mylan settle before trial?
Settlement offers certainty and avoids the expense of litigation; it is common in patent disputes to reach confidentiality agreements.
-
What is the significance of claim construction?
The court’s interpretation of patent claims determines infringement scope and validity defenses.
-
Can patent validity challenges succeed if the case settles?
No. Settlement typically resolves all disputes without adjudication of validity unless specified.
-
How does this case influence other ophthalmic patent litigations?
It underscores the importance of early claim interpretation and strategic settlement planning.
-
Are patent infringement cases in this domain predictable?
Not entirely, but high settlement rates and claim construction influence outcomes significantly.
References
[1] United States District Court for the District of Delaware. (2014). Kowa Company, Ltd. v. Mylan, Inc., 1:14-cv-02647.
